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Abstract: Bismuth compounds have been used extensively as medicines and in particular 
for the treatment of gastrointestinal ailments. In addition to bismuth’s well known 
gastroprotective effects and efficacy in treating H. pylori infection it also has broad  
anti-microbial, anti-leishmanial and anti-cancer properties. Aspects of the biological 
chemistry of bismuth are discussed and biomolecular targets associated with bismuth 
treatment are highlighted. This review strives to provide the reader with an up to date account 
of bismuth-based drugs currently used to treat patients and discuss potential medicinal 
applications of bismuth drugs with reference to recent developments in the literature. Ultimately 
this review aims to encourage original contributions to this exciting and important field. 
Keywords: bismuth; bismuth complexes; organobismuth compounds; medicinal chemistry; 
gastrointestinal; H. pylori; anti-microbial; anti-leishmanial; anti-cancer 
 
1. Introduction 
The use of metal-based drugs can be traced back to ancient times and has a rich and varied history [1]. 
Gold-based medicines were being used in China and the Middle East as far back as 3500 years ago and 
mercurous chloride (Hg2Cl2) was used as a diuretic during the Renaissance period, for example [2,3]. 
More recently in the early twentieth century Paul Ehrlich, who coined the term “chemotherapy”, 
developed Salvarsan, an arsenical, as a drug for the treatment of syphilis [4]. Contemporary medicinal 
inorganic chemistry though is a relatively young but vibrant research discipline. There are many 
excellent examples of metal-based therapeutics and diagnostics, metal chelators and inhibitors of 
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metalloproteins in the clinic, for example Figure 1, or in development and our knowledge of the roles of 
metal ions in biological systems is continuing to expand [3,5]. 
Figure 1. Structures of representative examples of a metal-based therapeutic and diagnostic, 
metal chelator and metalloprotein inhibitor [3,6]. 
 
The rational design of metal-based drugs is desirable. Careful selection of metals and manipulation 
of geometries, coordination numbers and redox states by selection of appropriate ligands can lead to the 
regulation of electronic, chemical and photophysical properties. Individual ligands also contribute 
greatly to structural diversity and modulate stability, ligand exchange kinetics and second coordination 
sphere interactions. In turn the prediction and control of the pharmacodynamics and pharmacokinetics 
of compounds together with the developments in relation to metallomics provide the opportunity to 
develop metal-based drugs with bespoke mechanisms of action [3,5]. 
Bismuth (Bi) has no known natural biological role, though there are references to Bi-containing 
medicines dating back to the late 18th century [7], and by the 20th century numerous different bismuth 
preparations were used as treatments for a variety of disorders including the treatment of war wounds, 
cholera infantum and gastroenteritis [8–10]. One of these preparations is well known and still in use 
today. Pepto-Bismol (bismuth subsalicylate, BSS), developed in 1901, is currently used to treat gastritis 
and dyspepsia. Other current bismuth medications include De-Nol (colloidal bismuth subcitrate, CBS) 
and the more recently developed Pylorid (ranitidine bismuth citrate, RBC) which are used for the 
treatment of ulcers and H. pylori infection [3]. 
Bismuth, thought to derive from the German word “wismuth” (white mass) is a relatively rare element 
and is the least abundant of the pnictogens or group 15 elements. In 1753 Claude Francois Geoffroy 
demonstrated bismuth to be a distinct element, as opposed to being elemental tin or lead. It is primarily 
found as bismuthinite (bismuth sulfide) and bismite (bismuth oxide) ores and sourced as a by-product 
of lead, copper and tin mining. It is naturally monoisotopic (209Bi) and can be considered to be the 
heaviest stable element, given its theoretical half-life is 1.9 × 109 years [11]. Radioactive bismuth-212 
(212Bi) and bismuth-213 (213Bi) in contrast have half-lives of 60.6 and 45.6 min respectively, and may 
have important roles to play as radiometals in radiopharmaceuticals [3,12]. 
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The metallic character of the group 15 elements increases down the group and Bi is considered 
metallic (or semi-metallic), as opposed to arsenic and antimony which are considered to be metalloids 
and nitrogen and phosphorous to be non-metals. The chemistry of arsenic, antimony and Bi is certainly 
less understood than that of nitrogen and phosphorous. Bi has a ground state electronic configuration of 
[Xe]4f145d106s26p3 and trivalent and pentavalent Bi, Bi(III) and Bi(V), respectively, are the two 
predominant oxidation states. In general the three 6p electrons are involved in bond formation and in the 
majority of compounds Bi is in the +3 oxidation state. Such compounds possess a so-called inert 6s2 pair 
of electrons, which can have a stereochemical effect. These two 6s electrons can be involved in bonding 
though and many examples of organobismuth(V) compounds are known [13]. BiF5 is the only Bi(V) 
halide known. Given Bi(V) is a very strong oxidant in aqueous solutions (BiV/BiIII E0 = 2.03 V) it is 
noteworthy that Bi(V) is generally not stable in biological solutions [14]. 
Organobismuth compounds have at least one direct carbon to Bi bond and represent an important 
class of organometallic compounds. The chemistry of organobismuth(III) and (V) compounds is continuing 
to develop and many classes have been reported including bismuth(III) containing-heterocylces (bismacycles 
and heterobismacycles) and triphenylbismuth(V) bis(carboxylate) complexes for instance [15–17]. 
Two key factors contribute to the coordination chemistry of Bi(III): (i) the 6s orbital is stabilized by 
relativistic effects resulting in the two 6s2 electrons being less readily available for bonding and a 
concomitant reduction in Lewis basicity (inert pair effect) and (ii) the coordination around Bi(III) 
centres, particularly when Bi(III) is bonded to electronegative atoms or groups, can be extended due to 
the significant degree of Lewis acidity as a result of: (a) the availability of unoccupied d and/or Bi-X σ* 
orbitals (where X is a halide for example) and (b) weak shielding of the 4f electrons, as per the lanthanide 
contraction [13,14]. Bi(III) is classified as a borderline Lewis acid according to the Hard Soft Acids 
Bases (HSAB) theory and therefore can form weak complexes with hard Lewis bases for example [18]. 
In general though Bi(III) is known to have a high affinity for oxygen, nitrogen and sulphur ligands. An 
affinity for thiolate ligands is considered to be an important property of Bi(III) in biological systems [14]. 
Bi(III) also has a relatively large ionic radius (1.16 Å), which can facilitate the formation of interesting 
complexes with higher coordination numbers and a wide range of geometries [19,20]. 
In regards to the biological chemistry of Bi the identification of potential targets of Bi-based drugs 
should be more readily achievable given the developments in relation to metallomics. It is  
well-established though that Bi can interact with: (i) nucleosides/nucleotides; (ii) amino acids/peptides 
and in turn (iii) proteins/enzymes [14]. 
Bismuth, for example, has been demonstrated to complex nucleosides as elegantly demonstrated by 
the crystal structure solved in Figure 2a. One Bi(III) centre (centre 1) is shown to bind to two adenosines 
via the deprotonated cis-2',3'diol groups and a second centre (centre 2) binds two adenosines via the 
deprotonated cis-2',3'diol groups and the nucleobase adenine via the imidazole N [21]. 
In addition a bismuth(III) complex of 1,4,7,10-tetrakis(2-pyridylmethyl)-1,4,7,10-tetraazacyclododecane 
(TPC) was demonstrated to bind calf thymus DNA. This interaction though is likely to be non-covalent 
interchelative [22]. 
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Figure 2. (a) Crystal structure of a Bi adenosine complex (CCDC: 634530) [21]; (b) Crystal 
Structure of Bi(Cys)3 (CCDC: 685969) [23]; Colour code:  C, grey; H, white; O, red; N, blue; 
S, yellow; Bi, purple; (c) Structures of cysteine (top) and glutathione (bottom). 
 
Bi(III) as mentioned has an affinity for thiolate ligands and thiolation of Bi(III) is thought to be the 
major biochemical fate of Bi(III) in cells and biological fluids [14,24]. Bi(III) readily binds to the 
cysteine thiolate groups of amino acids and peptides for example. The crystal structure of Bi(Cys)3 was 
solved by X-ray crystallography demonstrating that Bi(III) can bind three cysteine thiolate groups and 
at physiological pH (Figure 2b). The average Bi-S bond length is ca. 2.54 Å [23]. Furthermore Bi(III) 
has been demonstrated to bind to glutathione (GSH), a tripeptide antioxidant, which is found at high 
concentrations in animal cells (ca. 5 mM). ESI-MS data indicates that Bi(III) and GSH bind at ratios of 
1:1, 1:2 and 1:3 [25]. A previous study by Sadler et al. had shown that the deprotonated thiol groups of 
GSH were the strongest binding site for Bi(III) and Bi(GSH)3 is stable over a pH range of 2–10. A 
formation constant for Bi(GSH)3 of log K = 29.6 was determined, using 1H-NMR upon titration of GSH 
with [Bi(Hedta)]. Bi(GSH)3 is therefore more stable than Bi(III) complexes with edta (log K = 27.8) or 
citrate (log K = 13.5) for example [24]. Significantly spin-echo 1H-NMR experiments demonstrated that 
RBC reacts with GSH in red blood cells both in vivo and in vitro [24]. There are numerous studies of 
Bi(III) binding to longer peptide sequences [26–28]. 
Potocoki and co-workers investigated the coordination modes and thermodynamic stabilities of 
Zn(II), Cd(II), Bi(III), and Ni(II) complexes of the cysteine-rich N-terminal domain fragment of the 
ZIP13 zinc transporter (MPGCPCPGCG-NH2) by potentiometry, mass spectrometry, NMR, CD, and 
UV-Vis spectroscopy [29]. Bi(III) had the strongest affinity for the peptide sequence studied and the 
three cysteine thiolate groups as expected were identified as playing key roles in binding, Figure 3 [29]. 
Considerable research has been undertaken in relation to Bi(III) interactions with proteins and 
enzymes such as human serum transferrin (hTF) [30–34], metallothionein (MT), [31,35,36]. SARS 
coronavirus helicase [31,35,36], histidine rich protein (Hpn) [37,38], heat shock protein A (HspA) and 
urease [39–41] amongst others. 
hTF is an iron-transport glycoprotein. It binds Fe(III) tightly but reversibly and plays a key role in 
iron homeostasis, transporting Fe(III) from extracellular fluid to cytosol [42]. It is found at high 
concentrations in blood plasma and given it is generally only ca. 30% saturated with Fe(III) it can bind 
other metals such as Bi(III), Ru(III), Cu(II), Ni(II) and Zn(II) [14]. Yang et al. recently reported  
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the crystal structure of a Bi-bound hTF (BiNFeC-hTF) where the Bi(III) is found at the N-lobe, as per 
Figure 4a, and the Fe(III) at the C-lobe. The Bi(III) centre is bound by one tyrosine residue (Tyr188), a 
bidentate carbonate anion (synergistic anion), a tridentate nitrilotriacetate (NTA-3H) and a water 
molecule, Figure 4b. Bi(NTA-3H) was used in the preparation of BiNFeC-hTF [42]. Significantly in 
addition to providing valuable information on the binding mode of Bi(III) with hTF, this structure also 
strongly supports the theory that hTF does have a potential role in Bi-based drug delivery. 
Figure 3. Proposed structures of BiL complex; L is the N-terminus of ZIP13 
(MPGCPCPGCG-NH2). Hydrogens were removed for clarity; colours: grey, carbon; blue, 
nitrogen; red, oxygen; yellow, sulphur [29]. Reproduced with permission from [29]. 
Copyright (2011) American Chemical Society. 
 
Figure 4. (a) Anomalous electron density of BiNFeC-hTF. The hTF backbone is shown in 
grey ribbon with the residue Tyr188 and Bi(III) represented as stick and sphere models 
respectively. The anomalous electron density map (contoured at 10 σ), calculated from 
diffraction data collected at 0.92000 Å, is shown as red mesh and indicates the location of 
atoms that strongly absorb X-ray photons of this energy; (b) Coordination of Bi(III) in  
the N-lobe of BiNFeC-hTF. The gray 2Fobs − Fcalc map is contoured at 1.0 σ and the red 
anomalous electron map is contoured at 10.0 σ. The side chains of putative binding residues 
Asp63, Tyr95 and His249 are 6.7, 9.9 and 5.5 Å away from the Bi(III), respectively. 
Reproduced with permission from [42]. Copyright (2012) Nature Publishing Group. 
(a) (b) 
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Given the historical and contemporary contributions of Bi to medicinal chemistry, together with its 
interesting biological chemistry and reputation as a “green” non-toxic metal [11], there has been much 
research undertaken to date in relation to the development of novel Bi-based drugs as gastrointestinal, 
anti-microbial, anti-leishmanial and anti-cancer agents. There also has been a number of excellent 
reviews and books published in relation to the chemistry [13], biological chemistry [14] and medicinal 
properties of Bi-based compounds [43–46]. Though far from an exhaustive account this review strives 
to provide the reader with an up to date insight into the state of the art of Bi compounds with current and 
potential medicinal applications and encourage contributions to this important field. 
2. Gastrointestinal 
While bismuth medications were widely used at the start of the 20th century, for example for the 
treatment of syphilis, demand declined dramatically after the development of antibiotics. This decline 
continued until the discovery of H. pylori in the 1980s after which bismuth emerged as a component of 
effective treatments for many gastrointestinal disorders [47]. The efficacy of the bismuth preparations 
in the treatment of many of these disorders has been attributed to a number of different actions against 
H. pylori and cytoprotective effects in the gastric mucosa. 
H. pylori is a microaerophilic and neutralophilic Gram negative bacterium that has the ability to 
colonise the human stomach. It was first identified as a potential pathogen in 1984 when it was linked 
with idiopathic gastritis, inflammation of the lining of the stomach, by Marshall and Warren [47]. 
Subsequently H. pylori has become associated with dyspepsia, peptic ulcer and gastric cancer [48]. More 
recently H. pylori has been linked with extragastric diseases such as cardiovascular diseases, diabetes 
mellitus, sideropenic anemia, idiopathic thrombocytopenic purpura (ITP), autoimmune diseases  
and gallbladder cancer for example [49]. It is estimated that about 50 percent of the world’s population 
is infected with H. pylori, though the majority of infected people (>80%) do not develop any  
associated diseases [50]. 
H. pylori has developed a number of ways to survive and colonise the harsh acidic environment of 
the gastric mucosa and in turn induce chronic infection. One of these mechanisms is “acid acclimation” 
whereby in the acidic environment of the stomach, periplasmic pH is adjusted by regulation of urease, 
UreI (a pH-gated urea channel in the inner membrane of the gastric surface), and α-carbonic anhydrase [51]. 
First-line treatment for H. pylori is a standard triple therapy drug treatment: two antibiotics such as 
clarithromycin, amoxicillin, tetracycline or metronidazole in addition to a proton pump inhibitor  
(PPI) [52]. Significantly H. pylori infections are becoming increasingly difficult to eradicate due to drug 
resistance associated with overuse of antibiotics or non-adherence to treatment regimens [53,54].  
Bi-containing quadruple therapies therefore are being increasingly recommended as the first-line 
treatment in a number of countries [55]. As previously mentioned clinically used medications include 
bismuth subsalicylate (Pepto Bismol, BSS) colloidal bismuth subcitrate (De-Nol, CBS) and the more 
recently developed ranitidine bismuth citrate (Pylorid, RBS). Many of these Bi-based medicines are 
administered however without an exact understanding of their structure, behaviour in biological 
environments or indeed their mechanisms of action. 
Despite being in medicinal use for over 100 years the exact structure of BSS is not fully understood. 
In 2006 Andrews and co-workers though reported an important X-ray structure, which provides an 
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insight into the possible chemical nature of BSS. The structures were produced upon crystallisation of 
[BiHSal3], in acetone where H2Sal is salicylic acid, Figure 5a. The structures feature BiO clusters of 
formula [Bi38O44(HSal)26(Me2CO)16(H2O)2], Figure 5b, and [Bi9O7(HSal)13(Me2CO)5], Figure 5c. Each 
of these clusters contains a BiO core ranging from Bi9O7 to Bi38O44 for example [56].  
Figure 5. (a) Structure of salicylic acid; (b) Molecular structure of 
[Bi38O44(HSal)26(Me2CO)16(H2O)2] showing the shrouding of the Bi38O44 core (green = Bi, 
red = O) by 26 salicylate ligands (stick structures); (c) Molecular structure of 
[Bi9O7(HSal)13(Me2CO)5] (2) showing the shrouding of the Bi9O7 core (green = Bi, red = O) by 
13 salicylate ligands (stick structures) [56]. Subfigures b and c are reproduced from [56] 
with permission from John Wiley and Sons, 2006. 
 
Similarly CBS also presents challenges in regards to its structural characterization. Many different 
bismuth citrate complexes have been isolated and characterized by X-ray crystallography [57–62]. Given 
that speciation of Bi(III) citrate complexes is pH dependent, Jin et al. solved the structure of CBS in 
dilute HCl (pH = 3) using X-ray crystallography. Crystals of K(NH4)[Bi2(cit)2(H2O)2].4H2O revealed 
the presence of three types of Bi dinuclear units [Bi(cit)2Bi]2−, which assemble into a 3-D polymer, 
Figure 6b,c [62]. It was proposed that CBS may rearrange from colloidal particles such as [Bi6O4(cit)4]6− 
and [Bi12O8(cit)8]12− at neutral pH to 3-D polymers and sheets at low pH and the polymeric structure 
described may represent the protective “coating” found on ulcer craters post treatment [62]. The channels 
associated with the polymer matrix may also accommodate molecules of the histamine H2-receptor 
antagonist, ranitidine, in the widely used RBC. 
The bismuth carboxylate compounds, for example BSS, CBS, or RBC hydrolyse in the stomach 
forming insoluble bismuth salts or polymers, which are free to exert their bactericidal effects. BSS for 
example hydrolyses to release salicylic acid with the concomitant formation of bismuth oxychloride in 
gastric juice at pH 3. 
A single mechanism of action for the bactericidal activity in relation to H. pylori has yet to be 
established although experimental evidence suggests inhibition of the enzymatic activity of urease may 
be important [40,41,63]. Urease is a dinuclear nickel(II) enzyme, which as discussed previously plays a 
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O
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key role in acid-acclimation, facilitating the bacteria to grow in the highly acidic stomach. Zhang et al. 
for instance demonstrated both competitive and non-competitive inhibition of urease by Bi(III) from a 
number of complexes including RBC [41]. Using NMR spectroscopy and site-directed mutagenesis 
studies they suggest that bismuth(III) can bind to the highly conserved cysteine residue (Cys319) located 
at the entrance of the urease active site [41]. 
Figure 6. (a) Structure of citric acid; (b) Basic dimeric units [Bi(cit)2Bi]2− found in 
K(NH4)[Bi2(cit)2(H2O)2].4H2O with a C2 symmetry (dimer I) and an inversion center (dimer 
II/III). In dimer I, “W” represents a water molecule, while in dimer II/III, the “L” represents 
either an oxygen from a water molecule (dimer II) or a citrate carboxylate (dimer III).  
Colour code:  C, cyan; O, red; Bi, yellow; (c) Projection of the X-ray structure of 
K(NH4)[Bi2(cit)2(H2O)2].4H2O down the b axis. All potassium and ammonium ions, hydrogen 
atoms, and free lattice water molecules are omitted for clarity [62]. Subfigures b and c are 
reprinted with permission from [62]. Copyright (2003) American Chemical Society. 
 
Bi has also been shown to have a high affinity for two proteins associated with nickel homeostasis; 
Heat Shock Protein A (HspA) and H. pylori nickel binding protein (Hpn) [40,63,64]. Such interactions 
could also have knock-on effects on urease (a dinuclear Ni(II) enzyme) activity. [65–68]. HspA for 
instance is a molecular chaperone and assists with protein folding processes within the bacterial cell. It 
was also proposed to be involved in nickel homeostasis in H. pylori due to the presence of a nickel 
binding domain, a His and Cys rich C terminus, and the dependence of urease activation on the HspA 
gene. Bi(III) has also been reported to binds to apo-HspA with higher affinity than nickel(II) and induce 
structural reorganisation of the protein [64]. More recently it was proposed that irreversible binding of 
Bi(III) to an apical domain on HspA consisting of His45, Cys51 and Cys53 residues could interfere with 
zinc(II) ion delivery functions associated with HspA [69]. 
Additionally, CBS has also been shown to inhibit alcohol dehydrogenase (ADH) in H. pylori. ADH 
can produce acetaldehyde which forms adducts with phospholipids and exogenous proteins thereby 
damaging gastric cells and causing mucosal damage. Jin et al. suggest that inhibition of ADH is due to 
direct interference at the zinc binding sites through interaction with thiol groups [65–68]. Bi is also 
a 
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known to interact with/inhibit fumarase [70] translational factor Ef-Tu [71] phospholipase A [72] and 
pepsin [73]. Though the exact mechanism of action of the anti-bacterial activity associated with Bi has 
yet to be elucidated, the majority of available evidence points towards Bi interacting with cysteine 
residues on key proteins or Bi interference at thiol-containing metal binding sites in various target 
proteins in H. pylori. 
The precise mechanism by which Bi-based compounds heal ulcers is also not understood. Wagstaff 
proposed that CBS facilitates healing of the lesion by: (i) forming a Bi-glycoprotein complex in vitro, 
which acts as a protective coating and a barrier to HCl diffusion in the ulcer crater; (ii) stimulating 
prostaglandin E2 production with consequent secretion of alkali into the mucus layer; (iii) exhibiting an 
anti-bacterial effect against H. pylori as previously discussed [74]. The anti-ulcer effects of CBS may 
well be more complicated than straightforward precipitation at the ulcer crater though given it is known 
that even though CBS forms an insoluble precipitate at acidic pH, Bi is taken up by gastric and intestinal 
mucosal tissue and Bi is capable of interacting with numerous cellular proteins [14]. Further studies are 
undoubtedly required. 
Andrews and co-workers, subsequent to providing an invaluable insight into the possible structure of 
BSS [56], developed numerous families of novel Bi complexes with excellent anti-H. pylori activity and 
in turn have made an important contribution to this topic [75–82]. 
Andrews initial interest in the synthesis of Bi carboxylates via solvent mediated and solvent free methods 
lead to the development of polymeric Bi(III) 5-sulfosalicylate complexes. Reaction of 5-sulfosalicylic acid 
(H3Ssal, Figure 7a) with BiPh3 gave the heteroleptic carboxylate-sulfonate complexes [PhBi(HSal)H2O]∞ 
and [PhBi(HSal)EtOH]∞ where 5-sulfosalicylic acid is doubly deprotonated. Reaction of 5-sulfosalicylic 
acid with Bi(OAc)3 gave the homoleptic complex, {[Bi(HSal)(H2Sal)(H2O)3]2.2H2O}∞, where  
5-sulfosalicylic acid is found to be both singly and doubly deprotonated [75]. The molecular structure of 
[PhBi(HSal)H2O]∞ is shown in Figure 7b. The Bi centre is six-coordinate and the geometry is pentagonal 
pyramidal. The sterochemically active lone pair is trans to the phenyl group found at the apical position. 
The ethanol complex, [PhBi(HSal)EtOH]∞, was determined to be insoluble in aqueous solution whereas 
the two remaining complexes were remarkably water soluble resulting in solutions of pH 1.5. It is 
reported that the development of Bi complexes which are not water soluble at low pH is desirable given 
the links between potentially toxicity, absorption and water solubility. At pH 2 BSS, CBS and RBC are 
insoluble in aqueous solutions for example. Nonetheless all three complexes had reported MIC values 
of <6.25 µg/mL against three laboratory strains of H. pylori (B128, 251 and 26695). Such activities 
compare favourably with those of BSS (≤12.5 µg/mL) and 5-sulfosalicylic acid (>25 µg/mL) [75]. 
Having established that the 5-sulfosalicylic acid complexes had better activity than BSS, Andrews et al. 
were sufficiently encouraged to investigate the structural chemistry and anti-H. pylori activity of Bi 
complexes of mono-functional sulfonic acids [76,78]. Initially three bisphenyl Bi sulfonates were 
synthesized and characterised, [Ph2Bi(O3SR)]∞ where R is p-tolyl, mesityl or S-(+)-10-camphoryl 
(Figure 7c). These complexes were all insoluble in water and aqueous HCl solutions. The molecular 
structure of [Ph2Bi(O3S-Cam)]∞ is shown in Figure 7d. It consists of polymeric helical chain structure 
of four coordinate Bi atoms, which bridge two sulfonate O atoms. The geometry is distorted trigonal 
bipyramidal. These complexes were found to rearrange in solutions of acetone or dmso though to give 
for example mono-phenyl Bi bis-sulfonates, Bi tris-sulfonates or BiPh3. Regardless the presence of the 
single sulfonato ligands in [Ph2Bi(O3SR)]∞ produced a noteworthy increase in the anti-bacterial activity 
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of the complexes, which had MIC values of ≥6.25 µg/mL as compared to BiPh3 (>64 µg/mL) and the 
inactive sulfonic acids. 
Figure 7. (a) Structure of 5-sulfosalicylic acid; (b) Structure of [PhBi(HSal)H2O]∞ showing 
the basic dimeric unit. Reproduced from [75] with permission from The Royal Society of 
Chemistry; (c) Structure of the S-(+)-10-camphoryl sulfonic acid derivative; (d) Molecular 
structure of [Ph2Bi(O3S-Cam)]∞. Reproduced from [76] with permission from The Royal 
Society of Chemistry; (e) Molecular structure of [Bi8(O3SMes)20(SO4)2(H2O)6]. Lattice 
toluene and H atoms omitted for clarity. Reproduced from [78] with permission from The 
Royal Society of Chemistry. 
 
Subsequently given the potential toxicity associated with the release of benzene from phenyl bismuth 
compounds Andrews and co-workers concentrated on the development of Bi tris-sulfonates. Four 
complexes of general formula, [Bi(O3SR)3] were synthesized, where R = phenyl, p-tolyl, 2,4,6-mesityl 
or S-(+)-10-camphoryl. These complexes exhibited ‘remarkable’ anti-bacterial activity where MIC 
values as low as 0.049 µg/mL were determined for H. pylori strains B128 and 26695. In addition MIC 
values of 0.781 µg/mL were found for three of the complexes against a clinical H. pylori isolate 251, which 
were significantly lower than the values for BSS (12.5 µg/mL), CBS (12.5 µg/mL), RBC (8 µg/mL) and 
the corresponding [Ph2Bi(O3SR)] complexes (6.25 µg/mL), again highlighting the importance of the 
sulfonate group in relation to the anti-bacterial activity of this class of Bi complexes [78]. Interestingly 
the structure of [Bi8(O3SMes)20(SO4)2(H2O)6].(C7H8)7, which was produced on reaction of MeSO3H and 
BiPh3 in toluene was also solved, Figure 7e. This noteworthy structure was described by the authors as 
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a Bi(III)-sulfonate oligomeric cluster, where the eight Bi(III) centres are arranged in a wheel-type 
structure shielded by the sulfonate ligands [78]. 
Recently Andrews extended his interest to Bi(III) aminoarenesulfonate complexes [81]. Nine new 
tris-substituted Bi(III) aminoarenesulfonate complexes of general formula [Bi(O3S-RN)3], where  
RN = o-, m- and p-aminophenyl, 6-amino-3-methoxyphenyl, 2-pyridyl, o-aminonaphthyl, 5-aminonaphthyl, 
4-amino-3-hydroxynapthyl and 5-isoquinolinyl. The Bi complexes were found to be insoluble in water 
and 1 M aqueous HCl solution and also display notable in vitro activity against the H. pylori strains 
investigated with MIC values ranging from 0.049 to 12.5 µg/mL [81]. The o-, m- and p-aminophenyl 
complexes were particularly active against the clinical H. pylori isolate 251 with MIC values of  
0.049 µg/mL [81], which were lower than the MIC values previously reported for Bi tris-sulfonates 
(0.781 µg/mL) [78]. The identity of the ligand therefore clearly plays a key role in modulating  
the anti-bacterial effect as further demonstrated by incorporation of the amino functionality onto  
the sulfonate ligands. 
Andrews et al. also developed Bi(III) complexes of non-steroidal anti-inflammatories (NSAIDs) [77] 
and reported the structure and activity of “Bisprin”, a Bi(III) trisacetylsalicylic acid complex, where 
acetylsalicylic acid is aspirin, Figure 8c. All ten reported NSAID complexes of general formula [BiL3]n 
or [BiL3·(H2O)]n where L is an NSAID such as ibuprofen or mefenamic acid (Figure 8a,b) were found to 
exhibit excellent in vitro activity against H. pylori with MIC values of ≥6.25 µg/mL. NMR, FT-IR and 
mass spectrometric data indicated that the carboxylate groups chelated Bi(III) in a bidentate fashion [77]. 
Figure 8. Structures of: (a) ibuprofen, (b) mefenamic acid and (c) acetylsalicylic acid 
(aspirin); (d) Molecular structure of [Bi(asp)3]∞. Hydrogen atoms have been omitted for 
clarity. Reproduced from [80] with permission from The Royal Society of Chemistry. 
 
The structure of the tris acetylsalicylate Bi(III) complex, [Bi(O2C(C6H4)OAc)3]∞ ([Bi(Asp)3]), was 
solved by X-ray crystallography. It adopts a polymeric structure in the solid state. A dimeric section of 
the polymer is presented in Figure 8d, which shows that the dimer consists of two [Bi(Asp)3]. units, 
where two of the acetylsalicylate moieties per Bi(III) centre are bidentate chelating, and the units are 
joined by O atoms from two unsymmetrical bridging carboxylates. The coordination number is 7 in the 
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dimer, but 8 once polymerization is considered [80]. The complex exhibited similar in vitro activity as 
the previously reported Bi NSAID complexes against H. pylori strains investigated (B128, 251 and 
26695) with MIC values of 6.25 µg/mL [80]. 
Novel Bi(III) complexes of fluoroquinolones, a family of broad spectrum antibiotics, which also possess 
good anti-H. pylori activity, were developed by Shaikh and co-workers [83]. The complexes were 
characterised by molar absorptivity determination, differential scanning calorimetry, thermogravimetric 
analysis, Karl-Fischer aquametry, elemental analysis and FT-IR spectroscopy. The proposed structure 
of the Bi(III) norfloxacin complex is shown in Figure 9a as a representative example. All of the 
complexes developed exhibited better activity than their respective fluoroquinolone ligands against 16 
clinically isolated strains of H. pylori. Significantly the complexes were also found to be active against 
some of the fluoroquinolone resistant strains investigated with MIC values of 1–4 mg/L (1–4 µg/mL). 
Figure 9. (a) Proposed structure of Bi(III) norfloxacin complex; (b) Structure of hyaluronic 
acid; (c) Structure of saccharin. 
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Two publications from China report on Bi(III) complexes of a glycosaminoglycan [84] and 
polysaccharides [85]. Hyaluronic acid (HA, Figure 9b), is a naturally occurring glycosaminoglycan, 
which consists of repeating disaccharide units of N-glucosamine and D-glucoronic acid. It is highly 
negatively charged under physiological conditions and interacts readily with cations and has been 
demonstrated to bind to Cu(II), Ag(I), Au(III) and Fe(III) for example. Bi(III) complexes of high  
(1240 kDa), medium (675 kDa) and low molecular weight HA (240 kDa) were synthesized and 
characterised by elemental analysis, FT-IR, NMR and CD spectroscopy, X-ray diffractometry, X-ray 
photoelectron spectroscopy and thermogravimetric analysis. It was proposed that Bi(III) binds to the 
hydroxyl, carboxylate and amino groups of HA. All Bi(III) HA complexes regardless of molecular 
weight exhibited similar activity as CBS (MIC = 5 µg/mL) against three strains of H. pylori 
(NCTC11637, 26695 and J99). 
Two novel Bi(III) H. erinaceus polysaccharide (HEP) complexes were reported recently. H. erinaceus 
is an edible mushroom with well-known medicinal properties [85]. The bodies of H. erinaceus are used 
as home remedies to treat gastric and duodenal ulcers amongst other diseases. Two polysaccharides of 
197 and 20 kDa were isolated from H. erinaceus and reacted with Bi(NO3)3 to give HEP complexes, 
which were characterised by elemental analysis, FT-IR and CD spectroscopy, SEM, AFM, X-ray 
diffractometry and thermogravimetric analysis [85]. The two HEP were shown to exhibit modest activity 
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against the H. pylori strain investigated (NTCC11637) with MIC values of ≥160 µg/mL. The Bi HEP 
complexes exhibited good activity though with MIC values of 20 µg/mL, which are comparable with 
the activity of CBS in the same study. In addition the authors highlighted that the Bi HEP complexes 
developed have a lower Bi content than CBS [85]. 
The activities of the Bi(III) HA and HEP complexes both exhibited similar activity as CBS,  
the standard used in their studies. The use of high molecular weight glycosaminoglycans and 
polysaccharides is an interesting approach though neither authors speculate on the potential 
physiological impact of using such high molecular weight molecules on absorption for example. In 
addition characterisation of Bi(III) complexes of mono- or disaccaharides or derivatives of both would 
surely provide an insight into the exact nature of the interactions of Bi(III) and carbohydrates. Andrews 
has published reports on Bi(III) complexes of the artificial sweetener saccharin (Figure 9c) [86], and 
acetosulfame and cyclamic acid [82]. 
There are an increasing number of excellent publications on novel Bi(III) complexes as potential 
agents for the treatment of H. pylori. These publications feature complexes with well-defined, 
fascinating and varied structures and excellent anti-H. pylori activity. Nonetheless in depth mechanistic 
studies and in turn in vivo studies in relation to some of the more promising compounds are highly 
anticipated. Perhaps we should encourage/ challenge our colleagues in micro/molecular biology to take 
a more active interest in elucidating the mechanisms of action of Bi-based H. pylori drugs. In summary, 
eradication of H. pylori is an important goal for the global scientific community given its association 
with dyspepsia, peptic ulcer disease and gastric cancer. Further insight into the mechanism of action of 
Bi(III) anti-bacterial effects against H. pylori and ability to heal ulcers will certainly better inform the 
rational development of novel, effective and well-defined Bi-based drugs for the treatment of 
gastrointestinal disorders. 
3. Anti-Microbial 
In addition to H. pylori, Bi compounds have been effectively used to treat a host of bacterial 
associated infections such as syphilis (e.g., potassium bismuth tartrate, bismuth quinine iodide and 
iodobismitol), colitis (bismuth subnitrate, bismuth citrate), diarrhea (BSS and bismuth nitrate) and 
wound infections (bismuth oxide) [14]. 
BSS for example is well-known for its preventative and therapeutic properties in relation to diarrheal 
disorders. It has been demonstrated to exhibit in vitro anti-bacterial activity against enterotoxigenic  
E. coli, which is the principal bacterial cause of diarrhea in the developing world and so called “travelers’ 
diarrhea”. It has been proposed that BSS has the capacity to significantly reduce the toxin secretory 
activity of E. coli. In addition CBS and BSS have activity against another enteropathogen, C. difficile; 
CBS has an in vitro minimum inhibitory concentration of 90% of growth  (MIC90) of 128 µg/L [87], 
while BSS exhibited noteworthy activity in an in vivo hamster model of C. difficile colitis [88]. 
Interestingly, Sox and Olson reported that BSS could bind to E. coli (ATCC 10536), S. typhimurium 
and S. aureus. In turn binding was linked with bactericidal activity against E. coli and S. typhimurium 
though not against S. aureus [89]. Interestingly intracellular ATP levels in the E. coli strain were found 
to drop to 10% of initial levels, 30 min post exposure and extracellular ATP levels increased rapidly. It 
is proposed that exposure to BSS could affect membrane integrity and/or intracellular ATP synthesis. It 
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is also noteworthy that: (i) pretreatment of BSS with albumin decreased the rate of binding and killing 
of E. coli; (ii) the activity of BSS against E. coli was much more rapid at pH 3 as opposed to pH 7;  
(iii) salicylates also possess anti-bacterial activity and therefore may also contribute to the activity  
of BSS [14,89]. 
The biochemical targets of Bi-based compounds have been studied much more extensively for  
H. pylori than other bacteria. Nonetheless it is reasonable to assume that bacteria in general share some 
key biological targets of Bi-based compounds. 
Given the well-established anti-bacterial activity of Bi-compounds, there has been somewhat of a 
resurgence of interest in the development of novel Bi-based compounds as anti-bacterial agents. In 
contrast there are few if any historical reports in relation to the anti-fungal activity of Bi-based 
compounds and in turn limited evidence in relation to potential mechanisms of action. Nonetheless there 
have been some recent reports investigating the anti-fungal activity of Bi-based compounds though 
typically accompanying anti-bacterial data. 
There has been considerable interest in the potential biological activity of Bi(III) thiosemicarbazone 
complexes. Thiosemicarbazones, derived from condensation reactions between thiosemicarbazides and 
aldehydes or ketones, have rich coordination chemistry and are reported to have anti-parasitic,  
anti-bacterial and anti-cancer properties [90]. In addition it has been previously demonstrated that the 
anti-microbial activity of thiosemicarbazones can be enhanced on coordination to Sn, Cu and Ga [90]. 
Lessa et al. reported a family of Bi(III) thiosemicarbazones and bis(thiosemicarbazone) complexes as 
potential anti-bacterial agents. The complexes developed exhibited good anti-bacterial activity, where 
both the mono- and bis(thiosemicarbazone) Bi(III) complexes were better anti-bacterial agents than their 
corresponding free ligands (Figure 10a,b) against the Gram-positive bacteria; S. aureus, S. epidermidis 
and E. faecalis. The crystal structure of [Bi(2Ac4Ph)(dmso)Cl2]. (H2Ac4Ph = 1-(pyridin-2-yl)ethanone 
4-phenylthiosemicarbazone, Figure 10c, R = CH3) was solved, exhibiting the monoanionic coordination 
mode of the thiosemicarbazone via the Npy, Nimine and S. The increase in activity on complexation was 
particular evident against S. aureus, where for example the MIC for H2Fo4Ph (pyridine-2-carbaldehyde 
4-phenylthiosemicarbazone, Figure 10a, R = H) of 190 µM decreased to 6.1 µM for [Bi(2Fo4Ph)Cl2]. 
The MIC for tetracycline hydrochloride against S. aureus was found to be 0.3 µM though. Only one of 
the complexes tested, [Bi(2Fo4Ph)Cl2], exhibited enhanced activity as compared to its free ligand against 
the Gram-negative bacteria, P. aeruginosa. 
Lessa et al. proposed that an increase in solubility and bioavailability of Bi on coordination was key 
to the observed activity [90]. There are a number of additional reports in relation to novel bismuth 
thisosemicarbazone complexes, which were investigated not only as anti-bacterial agents but also  
anti-cancer agents [19,91–94]. These complexes feature in Section 5, where only their anti-cancer 
activity is discussed. 
A report also from the same group in Belo Horizonte, Brazil discussed the development of a series of 
Bi(III) complexes of 2,6-diacetylpyridine bis(benzoylhydrazone) derivatives (Figure 10d) and their  
anti-microbial activity against S. aureus, E. facecalis, S. epidermidis, P. aeruginosa and C. albicans. 
Hydrazone derivatives are known to possess anti-microbial and anti-tubercular activities [95], though in 
this study the ligands investigated were found to be inactive against the panel of microorganisms 
investigated. In contrast and in general upon coordination to Bi(III) the anti-microbial activity of the 
hydrazone derivatives was enhanced against the Gram-positive bacteria though less notably against the 
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Gram-negative bacteria (P. aeruginosa). Significantly the Bi(III) complexes were more active than their 
Sb(III) analogues and the Bi(III) hydrazone complex, [Bi(HAcpNO2Ph)Cl2], where H2AcpNO2Ph is  
2,6-diacetylpyridine bis(para-nitrobenzoylhydrazone), was found to be more active than tetracycline 
against S. aureus [95]. The X-ray crystal structure of [Bi(HAcpNO2Ph)(dmso)Cl] (Figure 10e), was 
solved on recrystallization of [Bi(HAcpNO2Ph)Cl2]. from acetone/dmso, again highlighting Bi(III) 
affinity for dmso. The anti-fungal activity of the Bi(III) complexes against C. albicans were also better 
than their Sb(III) analogues. The Bi(III) hydrazone complex, [Bi(HAcPh)Cl2], where H2AcPh is  
2,6-diacetylpyridine bis(benzoylhydrazone), (MIC: 44 µM) exhibited better activity than fluconazole 
(MIC: 59 µM), a well-known anti-fungal agent [95]. 
Figure 10. (a) General structure for pyridin-2-yl-derived 4-phenylthiosemicarbazones;  
(b) General structure for glyoxaldehyde bis(thiosemicarbazones); (c) Structure of 
[Bi(2Ac4Ph)(dmso)Cl2]. Reprinted with permission from [90]. Copyright (2012) John Wiley 
and Sons; (d) general structure for 2,6-diacetylpyridine bis(benzoylhydrazones) and  
(e) Molecular structure of [Bi(AcpNO2Ph)(dmso)Cl] (CCDC no.859622); Colour code:  C, 
grey; H, white; O, red; N, blue; S, yellow; Cl, green; Bi, purple [95]. 
 
Bi-based ciprofloxacin compounds were developed by Turel and co-workers [96,97]. Ciprofloxacin 
is a second generation fluoroquinolone antibiotic and development of Bi-based ciprofloxacin compounds 
was therefore an interesting strategy for the targeting of anti-microbial resisitance [96,97]. Two Bi(III) 
ciprofloxacin (cf) compounds were reported; (cfH2)(cfH)[BiCl6]·2H2O and (cfH2)2[Bi2Cl10]·2H2O  
(cf = 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-quinoline-3-carboxylic acid) [96,97]. No bonding 
between the quinolone and Bi(III) was observed though as the quinolones are either singly protonated 
(cfH) at piperazine N or doubly protonated (cfH2) at the carbonyl O and piperazine N. In 
(cfH2)(cfH)[BiCl6]·2H2O the six chloride ions coordinate Bi(III) with octahedral geometry to give 
[BiCl6]3− anions, whereas in (cfH2)2[Bi2Cl10]·2H2O the Bi(III) is coordinated by chloride ions to give a 
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centrosymmetric [Bi2Cl10]4− anion. Antimicrobial testing of (cfH2)(cfH)[BiCl6] against a panel of  
Gram-negative and Gram-positive bacteria and fungi was undertaken. In summary the compound 
exhibited similar activity as cf·HCl against the Gram-negative (E. coli, P. aeruginosa) and Gram-positive 
bacteria (S. aureus, E. facecalis, B. Subtilis, B. cereus) and no activity against the fungi (C. albicans,  
T. mentagrophytes and A. niger) investigated [96,97]. Both (cfH2)(cfH)[BiCl6] and (cfH2)2[Bi2Cl10] were 
also demonstrated to have similar activity as cf.HCl against S. viridians, Enterococcus sp. and  
S. haemolyticus G, which are resistant to ciprofloxacin. The authors appropriately discuss the potential 
impact on speciation of dissolving their compounds in DMSO and increasing the pH on diluting the 
compound with media and serum for example. BiCl3 for example is known to form BiOCl readily in 
aqueous solutions and Bi(III) dimethyl sulfoxide complexes will also potentially form when Bi(III) 
complexes are dissolved in dmso as evidenced by the structure in Figure 10c,e [95]. 
Murafuji and co-workers have developed heterocyclic organobismuth compounds as anti-fungal 
agents [98–100]. They initially identified a family of halobismuthanes derived from diphenyl sulfone as 
exhibiting promising anti-fungal activity against S. cerevisiae. Interestingly the X-ray crystal structure 
of the chlorobismuthane (Figure 11a), reveals the asymmetric unit contains two independent molecules 
with different coordination geometries at the Bi centre: (i) five coordinate Bi centre geometry through 
intramolecular Bi-O and intermolecular Bi-Cl interactions and (ii) seven coordinate Bi centre through 
intramolecular and intermolecular coordinated Bi-O bonds, which is an unusual geometry for 
organobismuth(III) compounds. Inhibitory effects were linked with the Lewis acidity of the Bi(III) centre 
which was proposed to be the active site [100]. 
Figure 11. Structures of heterocyclic organobismuth(III) compounds derived from diphenyl 
sulfone. (a) Chlorobismuthane; (b) A carboxylate bismuthane; (c) A dithiocarbamate bismuthane. 
 
Subsequent investigations of the effect of introducing substitutents onto the diphenyl sulfone scaffold 
and replacement of the chloro group attached to the Bi centre, were undertaken [98,99]. The findings 
suggest that in general there is an inverse relationship between lipophilicity of this family of compounds 
and anti-fungal activity; the higher the lipophilicity (ClogP values) the lower the activity of the 
halobismuthanes. Nonetheless a series of organobismuth(III) carboxylates, e.g., Figure 11b, display 
similar activity to chlorobismuthane (Figure 11a) even though they have higher ClogP values. 
Organobismuth(III) dithiocarbamate analogues, Figure 11c, were inactive, which was attributed to the 
lowered Lewis acidity due to the lower electronegativity of the sulphur atom bound to bismuth and also 
the high ClogP values associated with these compounds [98]. 
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A subsequent study of the influence of varying the structure of the carboxylate ligand on lipophilicity 
and anti-fungal activity suggested that the lipophilicity of the carboxylate compounds had no bearing on 
anti-fungal activity. Therefore the authors propose that the organobismuth(III) carboxylates separate 
inside yeast cells into a cationic heterocyclic bismuth scaffold and ionic carboxylate moiety with the 
bismuth scaffold playing the key role in anti-fungal activity [99]. 
Bi-based compounds are and have been successfully used to treat bacterial infections [101]. There 
has been recent interest in this area and encouraging results. Surprisingly though, there are fewer reports 
of novel Bi-based compounds as potential anti-bacterial agents in the literature relative to other  
metal-based compounds of gold and silver for example. Perhaps the anti-bacterial properties associated 
with Bi have been somewhat “forgotten” or the lack of solid evidence in relation to mechanism of action 
and the identification of concrete biomolecular targets is slowing progress in this area. There is a definite 
lack of reports in relation to Bi-based drugs as anti-fungal agents with little or no publications 
investigating possible anti-fungal mechanisms of action of Bi compounds. Accordingly exciting 
opportunities and challenges exist in this area. 
4. Anti-Leishmaniasis 
Leishmaniasis is a group of diseases caused by protozoan parasites of the Trypanosomatidae family 
and typically contracted by the bite of an infected female sand fly. In Asia, Africa and Southern Europe 
it is transmitted by the genus Leishmania whereas in North and South America it is transmitted by the 
genus Phlebotomus [102,103]. The epidemiology of the contracted disease depends on the strain and 
characteristic of the parasite species as well as other contributing factors. It is reported to be prevalent 
in 98 countries worldwide, where over 350 million people are at risk of contracting the disease.  
12 million are reported to have leishmaniasis with a further estimated two million new cases occurring 
every year [104]. 
There are three main forms of the disease; visceral, cutaneous and mucocutaneous. Visceral, caused 
by L. donovani and L. infantumis is the most dangerous form of the disease and if not treated promptly 
and completely can result in death very quickly [105]. It is reported that 300,000 cases result in about 
20,000 deaths every year for example. The cutaneous and mucocutaneous forms of the disease can be 
devastating; in the cutaneous form ulcers appear at the site of the bite, often resulting in scarring [106], 
whereas in the mucocutaneous form partial or complete destruction or depletion of the cutaneous and 
subcutaneous tissue occurs. 
Antimony (Sb)-based drugs have been used for the treatment of leishmaniasis. Tartar emetic 
(potassium antimony tartrate), a Sb(III) compound for example, developed at the start of the 20th 
century, was initially used and increased survival rates but was highly toxic to the patient [107]. Today 
however pentavalent substitutes such as pentosam (sodium stibogluconate) and glucantime (meglumine 
antimoniate) [108] (Figure 12a,b) are used as first-choice anti-leishmanial drugs in many countries due 
to their lower toxicity and more efficient therapeutic indices [14]. 
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Figure 12. Structures of (a) sodium stibogluconate and (b) meglumine antimoniate;  
(c) Overall view of the catalytic cleft of trypanothione reductase (TR) with Sb(III) from T. 
Infantum (PDB code 2W0H). The residues involved in trypanothione reduction are indicated 
as sticks [109]. The trypanothione substrate, modelled on the basis of the T. cruzi TR 
structure (PDB code 1BZL), is also indicated as sticks and coloured cyan. Reprinted with 
permission from [109]. Copyright 2012 American Chemical Society. 
 
The exact mode of action and site of action of the Sb-based drugs is for the most part unknown. It is 
widely accepted that the pentavalent Sb(V) is reduced to Sb(III) in the macrophages and parasitic cells 
by different thiols including cysteine, cysteine glycine and trypanothione [63,110]. Proposed 
biomolecular targets include the trypanothione synthase and reductase system. Trypanothione is a form 
of gluthatione, specific to the parasite in question. Trypanothione synthase, (TS), conjugates glutathione 
and spermidine to form trypanothione (N1-N8-bis(glutathionyl)spermidine), while trypanothione 
reductase (TR), keeps the molecule in its reduced form. The TS and TR systems are essential for survival 
of the parasites and the Typanosomatidae family as they rely on it to replace the redox functions of 
systems such as the glutathione reductase system present in other organisms. Crystal structures revealed 
the Sb binding site in TR and thus provided the molecular basis for antimonial inhibition of TR. Upon 
reduction of TR by NADPH, a disulphide bridge associated with two cysteine residues (Cys52 and 
Cys57) separates to form two thiolate groups, just 4.4 Å apart. The Sb(III) ion is coordinated in a 
distorted tetrahedral geometry by the two aforementioned cysteinate sulphurs, one threonine (Thr335) 
and one histidine (His461) from a second TR that forms a dimer complex. Comparison of the reduced 
TR Sb(III) NADPH complex structure with trypanothione bound TR from L. cruzi shows that Sb(III) is 
binding at the catalytic site of the enzyme (Figure 12c). Sb(III) therefore works by preventing interaction 
between the two sulphur atoms of the cysteine residues with His461, which acts as a proton exchanger 
in the reduction mechanism associated with glutathione reductase [111]. Ultimately the parasite’s ability 
to buffer oxidative stress is thought to be decreased [112]. 
An alternative proposal to explain the anti-leishmanial activity of Sb(III) has been published by 
Frezard et al. suggesting that Sb(III) targets important zinc finger binding domains responsible for many 
regulatory functions, e.g., DNA recognition, RNA packaging, protein folding and assembly, 
transcriptional activation, cell differentiation, growth and apoptosis. They showed that Sb(III) can 
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compete with zinc(II) for binding motifs found in Leishmanial parasites and proposed that this 
competitive binding may be responsible for the pharmacological activity of Sb drugs [113]. 
Resistance to Sb(V) first line drugs, as well as other contributing factors such as harsh dosage 
regimens and cardio- and hepato-toxicity have driven research to find novel drug compounds which 
could be used to treat leishmaniasis [82]. Given Bi close proximity in the periodic table and similar 
biological chemistry to Sb there is potential for Bi drugs to have similar biomolecular targets. Therefore 
Bi could be an ideal candidate for the development of novel metal-based drugs in this field. There are 
only a few, nevertheless important, examples of Bi-based compounds, which have been developed and 
evaluated as potential anti-leishmanial drugs [82,110,114,115]. 
Andrews, who has published extensively in relation to Bi compounds with activity against  
H. pylori, is also interested in developing Bi compounds with anti-leishmanial activity [82,110].  
The activity of four NSAIDs, naproxen (Figure 13a) mefenamic acid, ketoprofen and diflunisal and their 
corresponding homoleptic tris-carboxylato Bi(III) complexes, of general formula [BiL3]n and which were 
previously investigated for anti-H. pylori activity [77], were investigated against Leishmaniasis major 
promastigotes and human primary fibroblast cells for 48 h. Both groups showed activity only at the 
highest concentration tested (500 µg/mL) against L. major parasites, which is considered too high to be 
of practical use. A significant difference in the activity of naproxen and its tris-carboxylato Bi(III) 
complex was observed though, supporting a potential anti-leishmanial role for Bi. The Bi complexes 
were also more toxic towards human fibroblasts than the free acid also indicating that bismuth has a role 
in human cell toxicity [110]. 
Figure 13. Structures of (a) naproxen, (b) o-methoxybenzoic acid, (c) 3,5-diacetamido-benzoic 
acid and (d) 5-[(R/S)-2,3-dihydroxypropylcarbamoyl]-2-pyridinecarboxylic acid; (e) Molecular 
structure of [PhBi(o-MeOC6H4CO2)2(bipy)]. Reprinted with permission from [110]. 
Copyright (2011) Elsevier. 
 
In addition Bi(III) complexes of substituted benzoic acids; o- and m-methoxybenzoic acid (Figure 13b) 
o-nitrobenzoic acid, 3,5-diacetamidobenzoic acid (Figure 13c), and 5-[(R/S)-2,3-dihydroxypropyl 
carbamoyl]-2-pyridinecarboxylic acid (Figure 13d), were reported. Choice of ligand and reaction 
conditions dictated complex type produced; [BiL3(H2O)3], [PhBiL2], [PhBiL2(bipy)] (bipy-2,2-bipyridine), 
[PhBiL2(H2O)2] and [PhBiL2(H2O)]. Interestingly the free substituted carboxylic acids (examples 5–9) 
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displayed no activity against L. major parasites but their corresponding Bi derivatives were quantitatively 
toxic against the parasite even at low concentrations (1.95–200 µg/mL). The o-methoxybenzoic acid 
complex, [PhBi(o-MeOC6H4CO2)2(bipy)], possessed the lowest IC50 of 1.9 µg/mL. Its structure was 
solved by X-ray crystallography (Figure 13e). It is six-coordinate with distorted pentagonal pyramidal 
geometry. The stereochemically active lone pair is found trans to the phenyl group found at the apical 
position. When tested for potential human toxicity, against the fibroblast cell line, the Bi complexes in 
general were significantly more toxic than both the free substituted benzoic acids and the previously 
discussed Bi NSAID complexes. 
Andrews and co-workers recently reported a series of Bi(III) β-thioxoketonate complexes as  
anti-leishmanial agents. They hypothesised that Bi complexes with a more thermodynamically stable 
Bi-S bond would be less labile than for example a carboxylate analogue and in turn possess improved 
hydrolytic stability which should positively influence purity, reproducibility and activity in biological 
systems [82]. Though transition metal and p-block metal, including Bi, β-thioxoketonate complexes have 
been reported, the biological chemistry of the ligands or complexes were not explored [82]. 
Nine different β-thioxoketones complexes of formula R1C-(=O)CH2(=S)R2 (Figure 14a),  
and their Bi complexes of formula [Bi{R1C(=O)CHC(=S)R2}3] were synthesized. The structure  
of [Bi{C5H4NC(=O)CHC(=S)C6H5}3.dmso] was solved on attempted recrystallization of 
[Bi{C5H4NC(=O)CHC(=S)C6H5}3] in DMSO (Figure 14c). The complex is 7-coordinate and has 
disordered pentagonal bipyramidal geometry. As expected the β-thioxoketonate ligand chelates the 
Bi(III) centre in a bidentate fashion via the O and S atoms. 
Figure 14. (a) Structures of β-thioxoketones; (b) Structure of L5; (c) Molecular structure of 
[Bi{C5H4NC(=O)CHC(=S)C6H5}3.dmso]. Reproduced from [82] with permission from The 
Royal Society of Chemistry. 
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The bismuth derivatives, free acid and BiPh3 were tested for their in vitro toxicity activity against  
L. major promastigotes and primary human fibroblasts. The β-thioxoketones were selectively toxic to  
L. major promastigotes as opposed to the primary human fibroblasts. L1 (Figure 13a), for example had 
similar activity as the antibiotic, Amphotericin B, with ca. 80% parasite kill at 25 µM (6 µg/mL). In 
contrast and surprisingly the Bi(III) thioxoketonates were in general less toxic than their free ligands. 
The L5 Bi complex, [Bi{C5H4NC(=O)CHC(=S)C6H5}3]. (B5) was the most active of the series with  
ca. 80% parasite kill at 50 µM (46 µg/mL). Though B5 was less toxic to the fibroblasts compared against 
the L. major promastigotes, in general the Bi complexes displayed little or no selectivity, which would 
suggest that they are not suitable candidates for the treatment of Leishmaniasis. Lipophilicity, stability 
and low lability were highlighted as factors that may be important in determining cellular uptake and 
interactions with biomolecular targets. 
These two contrasting studies highlight that Bi does have anti-leishmanial properties though such 
properties are modulated by ligand choice as well as factors such as lipophilicity and stability. The 
development of compounds with selective anti-leishmanial activity is the challenge. 
Demicheli and co-workers are also interested in the development of Bi-based compounds as  
anti-leishmanial agents [114,115]. In 2012 they reported Sb(III) and Bi(III) complexes of dipyrido[3,2-
a:2',3'-c]phenazine (dppz), [Sb(dppz)Cl3] and [Bi(dppz)Cl3] (Figure 15a) which were characterized by  
FT-IR and NMR spectroscopy, elemental analysis and X-ray crystallography (Sb complex only). These 
complexes, along with the free ligand dppz were tested against wild type (WT) and Sb resistant (SbR) 
strains of Leishmania infantum chagasi and Leishmania amazonensis, which are associated with visceral 
and cutaneous Leishmaniasis respectively. 
Figure 15. Proposed structures of (a) [Bi(dppz)Cl3] and (b) [Ph3Bi(AcSA)2]. 
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Dppz showed intrinsic activity against both the WT and SbR strains investigated with IC50 varying 
from ca. 0.8 to 2 μM. As expected the Sb(III) and Bi(III) complexes showed a higher activity against 
the same strains (ca. 0.6–1 μM), indicating a role for the Sb(III) and Bi(III) in the activity of the 
complexes. Interestingly the Sb(III) and Bi(III) compounds, which had very similar activity, were at 
least 77 and 2400 times more active than tartar emetic against the WT and SbR strains respectively. Both 
complexes are 80 times more active than the trivalent BiCl3 and SbCl3 compounds than the WT strains 
also. This was interesting to note as this suggests that the metal alone is not sufficient to have anti 
leishmaniasis activity but perhaps as proposed improves the activity of dppz through complexation [115]. 
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It was hypothesised that the leishmanicidal activity of the dppz complexes may be via dppz 
intercalation at the parasites DNA and/or positive modulation of the lipohilicity/hydrophilicity of dppz 
on complexation. In this study the less lipophilic (more hydrophilic) the compound the better activity 
against leishmaniasis for example [115]. A similar observation in relation to lipophilicity was observed 
in Andrews recent study in relation to the activity of the β-thioxoketones, which were generally more 
active but less lipophilic than their Bi(III) complexes [82]. 
Significantly the cytotoxicity studies of the Bi(III) and Sb(III) complexes against mouse peritoneal 
macrophages (MPM) showed toxicity occurs at a 6-fold higher level as compared to the active concentration 
against leishmaniasis promastigotes, indicative of the potential selectivity of these compounds. 
In a very recent study, two novel triphenyl Sb(V) and two triphenyl Bi(V) complexes of benzoic acid 
derivatives and their respective free ligands were screened for activity against L. amazonensis and  
L. infantum promastigotes. Complexes of the type [Ph3ML2] were developed where HL is acetylsalicylic 
acid (aspirin, AcSAH) or 3-acetoxybenzoic acid (3-AcBAH) and characterised by FT-IR and NMR 
spectroscopy, elemental analysis and X-ray crystallography (Sb complex only) [114]. The proposed 
structure for [Ph3Bi(AcSa)2] is shown in Figure 15b. 
As per Table 1 the benzoic acid derivatives show no activity against the leishmaniasis strains at  
48 h treatment. The novel organo Bi(V) benzoic acid derivative complexes (2.9–8.6 µM IC50 range) 
were more active than the corresponding Sb(V) complexes (8.9–30.7 µM IC50 range) thought both were 
notably more active than tartar emetic (83–100 µM IC50 range). Significantly the Sb and Bi salts, 
Ph3SbCl2 and Ph3BiCO3 were at least as active as the complexes and in fact Ph3BiCO3 was the most 
active compound tested, suggesting that the ligands probably dissociate from the complexes prior to 
them exerting their activity.  
Table 1. Inhibitory concentrations of triphenyl Sb(V) and triphenyl Bi(V) complexes of 
acetylsalicylic acid and 3-acetoxybenzoic acid, acetylsalicylic acid, 3-acetoxybenzoic acid 
and metal salts against L. amazonensis and L. infantum species promastigotes at 48 h [114]. 
Compounds 
L. infantum Strain L. amazonensis Strain 
IC50 (μM) ± SEM 
Acetylsalicylic acid (AcSAH) 8.99 × 103 ± 1.89 × 103 2.18 × 106 ± 0.12 × 106 
Ph3Sb(AcSA)2  13.3 ± 0.74 30.7 ± 3.43 
Ph3Sb(3-AcBA)2·CHCl3  12.2 ± 0.91 8.9 ± 0.36 
Ph3SbCl2  13.2 ± 2.03 9.3 ± 0.26 
3-Acetoxybenzoic acid (3-AcBAH) 3.19 × 107 ± 0.55 × 107 1.40 × 107 ± 0.12 × 106 
Ph3Bi(AcSA)2 8.6 ± 1.36 8.5 ± 0.56 
Ph3Bi(3-AcBA)2  4.0 ± 0.39 2.9 ± 0.17 
Ph3BiCO3 1.1 ± 0.37 2.7 ± 0.34 
Tartar emetic 100 ± 3 83 ± 1  
Cytotoxicity against mammalian cells was investigated by means of MTT assay on mouse peritoneal 
macrophages (MPM). The organo Sb(V) complexes were found to be approximately 10 fold less toxic 
than organo Bi(V) complexes, and are hence more selective to the leishmanial strains in this study. 
Leishmaniasis is prevalent in many countries worldwide. It is a devastating disease but one which is 
curable once treated correctly and rapidly. Nonetheless resistance, compliance and toxicity are factors 
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associated with current treatment options. Therefore there has been recent interest in developing new 
Bi-based drugs which can successfully treat leishmaniasis and Bi compounds with promising activity 
have been reported. The continued development and evaluation of novel Bi compounds and 
determination of Bi effect on the TS and TR systems and other potential leishmanial biomolecular 
targets, will certainly further the cause of Bi- compounds as potential anti-leishmanial agents. 
5. Anti-Cancer 
Cancer is a major cause of death and disease worldwide and according to WHO cancer related deaths 
are predicted to rise to over 21 million by 2030 [116]. Over the past 30 years platinum compounds have 
played a very important and well documented role in treating cancer. In spite of the clinical and 
commercial success of platinum compounds there are well-known drawbacks associated with their use 
such as toxicity, limited activity and resistance [5]. Nonetheless a vast amount of research has been 
undertaken to date in relation to non-platinum-based compounds as anti-cancer agents. Radiometals 
aside, it may therefore be surprising to note that arsenic is the only other metal whose compounds are 
approved for the direct treatment of cancer, (acute promyelocytic leukaemia, APL) [3]. It may also be 
surprising given the success of As2O3 in the treatment of APL, that there is a lack of reports in relation 
to the development of novel Bi-based anti-cancer chemotherapeutics. A selection of contributions to this 
area is outlined below. 
A number of recent publications from Henan University, Kaifeng, China contribute to the story in 
relation to bismuth thisosemicarbazone or thiocarbonohydrazone complexes as anti-cancer  
agents [19,91–94]. As previously mentioned, in relation to the development of Bi-based anti-bacterial 
agents, thiosemicarbazones, have rich coordination chemistry and are reported to have anti-parasital, 
anti-bacterial and anti-cancer properties. Ming-Xue Li et al. developed a Bi(III) complex of 2-acetylpyrazine 
N(4)-phenylthiosemicarbazone (HL), [Bi(L)(NO3)2(CH3OH)]. The structure of this complex was solved 
by X-ray crystallography (Figure 16a) [92]. This complex is 7-coordinate, accounting for the inert 
electron pair, and possesses pentagonal bipyramidal geometry. The tridentate monodeprotonated 
thiosemicarbazone N2S ligand as one might expect occupies the pentagonal plane. This Bi(III) complex 
nonetheless was found to be significantly less active (IC50 = 46.2 µM) than cisplatin (1.2 µM) and indeed 
the free ligand (12.3 µM) against K562 (leukaemia) cells on 24 h treatment [92]. 
A separate report later in 2012 features a Bi(III) complex of 2-acetylpyridine, N(4)-pyridyl 
thiosemicarbazone (HL), [Bi(HL)(NO3)3] [91]. The molecular geometry of this 9-coordinate complex, 
accounting for the inert electron pair (6s2), is one dodecahedral. The neutral thiosemicarbazone coordinates 
the Bi(III) via its pyridine nitrogen, imine nitrogen and thione sulphur to give two five-membered chelate 
rings, Figure 16b. This complex exhibits good cytotoxicity (IC50 <10 µM) against a panel of cancer cell 
lines; K562, (leukaemia), HCT116 (colorectal), HepG2 (hepatocellular) and HeLa (cervical) cancer 
cells. Significantly and in contrast to the 2-acetylpyrazine N(4)-phenylthiosemicarbazone complex 
exhibits similar cytotoxicity (1.8 µM) as cisplatin (1.2 µM) and superior cytotoxicity than the free ligand 
(>100 µM) and Bi(NO3)3 (41.2 µM) against the K562 leukaemia cells. Results from annexin-V FITC/PI 
double staining and caspase-3 activation experiments on HepG2 cells treated with this complex, suggest 
that the cytotoxicity observed may be due to induction of apoptosis [91]. 
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Figure 16. Molecular structures of (a) a Bi(III) complex of 2-acetylpyrazine  
N(4)-phenylthiosemicarbazone (HL), [Bi(L)(NO3)2(CH3OH)]. Reprinted with permission 
from [92]. Copyright (2012) Elsevier and (b) a Bi(III) complex of 2-acetylpyridine,  
N(4)-pyridyl thiosemicarbazone (HL), [Bi(HL)(NO3)3] and polyhedron showing dodecahedral 
geometry around the bismuth atom of the asymmetric unit. Reproduced from [91] with 
permission from The Royal Society of Chemistry. 
 
A Bi(III) complex of the pentadentate ligand 2,6-diacetylpyridine bis(4N-methylthiosemicarbazone), 
H2L, Figure 17a, [Bi(H2L)(NO3)2]NO3 was also reported [19]. The Bi(III) centre is nine-coordinate 
where the neutral pentadentate thiosemicarbazone ligand coordinates via three nitrogens and two sulphur 
atoms (N3S2) and two nitrate ions coordinate via the four oxygen atoms as shown in the X-ray crystal 
structure (Figure 17b). 
The in vitro cytotoxicity of this complex was investigated also against the K562 leukaemia cancer 
cell line for 24 h. The Bi(III) complex has a lower in vitro IC50 value (26.8 µM) than both the free ligand 
(H2L, 82.3 µM) and Bi(NO3)3·5H2O (41.2 µM) but not compared to the previously reported  
2-acetylpyridine, N(4)-pyridylthiosemicarbazone complex (Figure 16b) which has an IC50 value of  
1.8 µM. Regardless the activity of this complex was investigated in vivo in Kunming mice by caudal 
injection [19]. The LD50 was determined to be 44.7 mg/kg and effective H22 xenograft tumour growth 
inhibition (61.6%) was demonstrated after treatment at 10 mg/kg [19]. 
Yan-Ke Li et al. developed a 7-coordinate Bi(III) thiosemicarbazone complex but of 2-acetyl- 
pyridine-N(4)-phenylthiosemicarbazone (HL), [Bi(L)(NO3)2(CH3CH2OH)] (Figure 18a). This complex 
differs only by the substitution of a pyridine ring for a pyrazine ring and a solvating ethoxide as opposed 
to a methoxide in the 2-acetylpyrazine N(4)-phenylthiosemicarbazone complex, Figure 16a, though 
displays far superior cytotoxicity activity [93]. It has sub-10 µM IC50 values against K562, HCT116, 
HepG2 and HeLa cancer cells and somewhat similar activity as cisplatin against K562 cells as was the 
(a) (b) 
N
N
N
N HN
S
Bi
O
O ON N
H CH3O
O
O
O
N
N
N HN
S
Bi
O O
N NO
O O
O
N
O O
N
O
Molecules 2014, 19 15282 
 
 
case for 2-acetylpyrazine N(4)-phenylthiosemicarbazone complex, Figure 16b. Li et al. provide a 
valuable insight into the potential mechansim of action of this class of compounds by demonstrating that 
2-acetylpyridine-N(4)-phenylthiosemicarbazone Bi(III) complex promotes a dose-dependent apoptosis 
in HepG2 cells, which is associated with an increase in intracellular concentrations of ROS and reduction 
in mitochondrial membrane potential [93]. 
Figure 17. (a) Structure of 2,6-diacetylpyridine bis(4N-methylthiosemicarbazone) (H2L);  
(b) Molecular structure of [Bi(H2L)(NO3)2]NO3 atomic numbering and polyhedral showing 
distorted geometry around the Bi atom. Reprinted with permission from [19]. Copyright 
(2012) American Chemical Society. 
 
Figure 18. Structure of (a) a Bi(III) 2-acetylpyridine N(4)-phenylthiosemicarbazone (HL) 
complex, [Bi(L)(NO3)2(CH3CH2OH)]; (b) a Bi(III) bis(2-acetylpyrazine) thiocarbonohydrazone 
(H2L) complex, [Bi(HL)(NO3)2(H2O)]. 
 
There has been considerable interest in the development of Bi(III) thiosemicarbazone complexes as 
both potential anti-cancer and anti-bacterial agents, which has resulted in the development of interesting 
complexes with some good activity. Nonetheless the strategy of coordinating Bi(III) to thiosemicarbazones 
to enhance the activity of the ligands clearly does not always work [92]. Therefore the development of 
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effective Bi(III) complexes of thiosemicarbazones as anti-cancer agents will certainly require a greater 
understanding of the activity of the ligands and biomolecular effects of the corresponding Bi(III) complexes. 
Zhang et al. developed Bi(III), Ga(III) and diorgano Sn(IV) complexes of bis(2-acetyl- 
pyrazine)thiocarbonohydrazone (H2L). The Bi(III) complex, [Bi(HL)(NO3)2(H2O)] (Figure 18b) was 
found to be the most cytotoxic of the compounds studied and 14-fold more cytotoxic than the free 
thiocarbonohydrazone ligand against HepG2 liver cancer cells [94]. The authors preliminary investigation 
into a possible mechanism of action of these complexes suggest that the apoptosis observed is connected 
with generation of reactive oxygen species (ROS) production and also reduction of mitochondrial 
membrane potential [94]. 
Three recent publications from Belo Horizonte, Brazil describe novel Bi(III) complexes with cytotoxic 
activities. De Oliveira and co-workers developed a Bi(V) complex of lapachol (Lp), a natural product with 
reported anti-tumour, anti-malarial and anti-leshmanial properties. Such properties are attributed to reactive 
oxygen species generation and/or DNA interchelation [117]. The dinuclear Bi(V) complex, (Lp)2(Ph3Bi)2O, 
where the Bi atoms are bridged by one O atom, Figure 19a, was found to have a favourable IC50 value 
(1.8 µM) as compared to cisplatin (1.0 µM) against K562 cells. Significantly this Bi(V) complex was 
also more cytotoxic than the free ligand (ca. 5-fold), a reported Sb(V) lapochol complex, (Lp)(Ph3Sb)OH 
(c. 20-fold) and Ph3BiCl2 (c. 17-fold) and determined to be stable in aqueous solution [117]. This is a 
rare example of an organobismuth(V) complex that exhibits noteworthy in vitro cytotoxicity. 
Figure 19. Structure of (a) (Lp)2(Ph3Bi)2O, (b) [Bi(HAcPh)Cl2], (c) [BiCl3(Spy)3],  
(d) bichlorodibenzo[c,f][1,5]thiabismocine compound and (e) general structure of Bi 
xanthate complexes. 
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Ferraz et al. report a series of Bi(III) complexes of 2,6-diacetylpyridine bis(benzoylhydrazone) 
derivatives. Hydrazone derivatives are known to possess anti-microbial and anti-tubercular activities [95]. 
The Bi(III) hydrazone complex, [Bi(HAcPh)Cl2] (Figure 19b) where H2AcPh is 2,6-diacetylpyridine 
bis(benzoylhydrazone), proved to be most active against a panel of cancer cell lines (Jurkat, HL60,  
MCF-7 and HCT-116). This compound was more cytotoxic than the free ligand, corresponding Sb(III) 
complex, [Sb(HAcPh)Cl2] and also cisplatin. The reported Bi(III) complex of the corresponding  
p-choro-benzoylhydrazone derivative, [Bi(HAcpClPh)Cl2], perhaps represented the best drug candidate 
though as it possessed a superior therapeutic index once activities against the normal cell line, PBMC, 
were considered [95]. 
Subsequently Marzano and co-workers developed a novel bismuth complex of sulfapyridine (SpyH), 
[BiCl3(Spy)3] (Figure 19c) [118]. Sulfapyridine is a sulfonamide anti-bacterial, the first synthetic 
antibiotics to be administered clinically. It is no longer used medicinally in humans in part due to 
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resistance but also a potential risk of developing agranulocytosis or leukopenia. Nonetheless the Bi(III) 
complex of sulfapyridine was demonstrated to inhibit the growth of leukemia cells, K562, with an IC50 of 
44 µM at 72 h treatment. Sulfapyridine in contrast had an IC50 > 100 µM against the same cell line [118]. 
In Japan, Iuchi et al. investigated the anti-cancer activities of a family of heterocyclic organobismuth(III) 
compounds previously investigated as an anti-microbial agents [100,119]. These compounds exhibited 
significant anti-cancer activity against a broad panel of cancer cell lines [120]. The authors focused on 
the activity of the bi-chlorodibenzo[c,f] [1,5]. thiabismocine compound (Figure 19d) against the human 
promyelocytic leukemia cell line, HL-60, due to (i) its submicromolar IC50 values against a panel of 
leukemia cell lines at 12 h treatment (e.g., HL-60, IC50 = 0.151 µM) and (ii) the propensity of the fellow 
group 5 compound arsenic trioxide to effectively treat acute promyelocytic leukemia [3]. It is noteworthy 
that the authors undertook a relatively comprehensive investigation into the mechanism of action of this 
heterocyclic organobismuth(III) compound. 
The compound induced apoptosis at low concentrations (0.22–0.44 µM) resulting in internucleosomal 
DNA degradation, nucleus condensation/fragmentation and laddering [120]. At higher concentrations 
(>1.1 µM) acute necrosis was observed. Intracellular ATP levels and/or ROS concentration were 
proposed as key factors determining cell death by apoptosis or necrosis. Caspase-3 (effector) and 
caspase-9 (initiator, intrinsic or mitochondrial pathway) were determined to participate in the observed 
apoptosis whereas caspase-8 (initiator, extrinsic or death receptor signaling pathway) to a lesser extent. 
Iuchi et al. surmised that generation of ROS and release of cytochrome from mitochondria contributed 
to the anti-cancer activity of these compounds. 
An interesting article authored by Friebolin et al. describes the anti-cancer activity of a series of 
xanthate complexes of Bi, Cu, Au, Ni, Pd and Rh. Eighteen bis(O-alkyldithiocarbanato) metal complexes 
were synthesized in total and their anti-cancer activity at pH 6.8 and 7.4 against Calu-6 (lung) and  
MCF-7 (breast) cancer cell lines were investigated and compared to the activity of cisplatin and  
bis(O-alkyldithiocarbanato) Pt complexes. The Pd complexes performed the best, followed by Bi 
complexes such as those shown in Figure 19e. Bi(S2COR)3 where R is isopropyl for example has an IC50 
of 11.2 µM as compared to cisplatin’s 27.21 µM. In addition the Bi complexes were also found to be 
more active at pH 6.8 than 7.4 [121]. pH 6.8 was investigated given the assertion that solid tumours 
often have pH’s of 6.8 and lower [121]. 
Carraher, Jr. and coworkers are interested in the development of biomedically or biologically active 
Group VA metal-containing polymers [122]. Recent example of this work describe organoarsenic, 
oraganoantimony and oragnobismuth polymers of biologically active monomers such as glycyrrhetinic 
acid (GAH2) [123], thiodiglycolic acid (TGH2) [124] and norfloxacin (NFH2) [125] as potential  
anti-cancer agents, Figure 20. IR spectroscopy, 1H-NMR and MALDI MS were employed to characterise 
the reported polymers. 
GA for example is a pentacyclic triterpenoid with medicinal properties. It is an inhibitor of  
15-hydroxyprostaglandin dehydrogenase and delta-13-prostaglandin which gives rise to increased levels 
of prostaglandins. It is also is a potent inducer of mitochondrial permeability transition and can therefore 
trigger the pro-apoptotic pathway [123]. The organometallic Bi polymer of GA, BiPh3/GA, is described 
as a mixture of bridging and non-bridging structures about the Bi though largely non-bridging and 
asymmetric. Characterisation is consistent with the formation of poly ether esters, Figure 20b. The 
reported chain length is 2500. The organometallic Bi polymer of GA, BiPh3/GA exhibited moderate 
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activity against a pancreatic cell line (PANC-1, EC50 = 3800 ng/mL) though cisplatin (AsPC-1,  
EC50 = 1400 and PANC-1, EC50 = 340 ng/mL) and the organometallic antimony polymer of GA, 
SbPh3/GA (AsPC-1, EC50 = 1900 and PANC-1, EC50 = 1700 ng/mL) exhibited superior activity against 
both pancreatic cell lines tested [123]. 
Figure 20. Structures of (a) GA, (c) TG and (e) NF and proposed structures for repeat units of 
the polymers; (b) BiPh3/GA, (d) BiPh3/TG and (f) BiPh3/NF where R is a chain extension. 
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The polyamine ester organometallic Bi polymer of norfloxacin, BiPh3/NF (Figure 20f) represents a 
better example of the anti-cancer potential of Bi containing polymers. Norfloxacin as previously 
mentioned is a fluoroquinolone broad spectrum antibiotic. The BiPh3/NF polymer is predominantly a 
bridging structure about the Bi and IR spectroscopy indicates the formation of Bi-O and Bi-N bonds. 
The reported chain length is 2100. The Bi polymer exhibited superior activity than the antimony and 
arsenic-base polymers in four (pancreatic, breast, colon and prostate) out of the six cancer cell lines 
tested with marked activity against the pancreatic cell line, PANC-1 (EC50 = 14 µg/mL) which was also 
superior to that of cisplatin (EC50 = 340 µg/mL). The Bi polymer also exhibits selectivity when its 
cytotoxicity for the breast cancer cell line, MDA MB-231 (EC50 = 0.61 µg/mL) is compared to its toxicity 
towards the WI-38 normal embryonic human lung fibroblast cells (EC50 = 4.2 µg/mL). The results in 
this study are encouraging and the anti-cancer activity of Bi containing polymers certainly merits  
further investigation. 
Many of the Bi-containing compounds developed to date and evaluated as potential anti-cancer agents 
were predominantly developed: (i) given that Bi-containing compounds have exhibited cytotoxicity in 
the past or exhibit other “biological activity” such as anti-bacterial activity or (ii) as Bi-containing 
complexes which possess ligands previously determined to be cytotoxic. Tentative references have been 
made to the presence of Bi potentially enhancing the lipophilicity of particular ligands or indeed ligands 
and Bi acting in a synergistic manner. It is also noteworthy that such compounds appear to exhibit more 
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favourable cytotoxicity against leukaemias as opposed to cancers associated with solid tumours, which 
resonates with the activity of As2O3 for example. 
In the main there is a distinct lack of information regarding potential mechanisms of action of  
Bi-containing compounds as anti-cancer agents though recently investigators have strived to gain a better 
understanding in relation to how their compounds may exert their cytotoxic effects. Presumably Bi(III) 
targets non DNA sites and in turn Bi-containing compounds possess different anti-cancer mechanisms 
of action as compared to classical Pt anti-cancer drugs. The recent elucidation of PML, a zinc finger 
protein, as being the target for As2O3 in relation to its activity against APL and provision of evidence 
that As2O3 interacts with cysteines located in zinc fingers within the RING domain and B2 motif of PML, 
may serve as inspiration for those interested in discovering a relevant Bi(III) anti-cancer target [3]. 
The growing interest in the development of novel Bi-containing compounds as anti-cancer agents is 
extremely positive and the activity of reported compounds certainly supports the view that Bi-containing 
drugs do have a potential role to play as effective anti-cancer agents. Nonetheless a more rational 
approach to the design of such compounds is desirable and surely will be more productive. Identification 
of the exact role Bi in targeting cancer is a prerequisite. Subsequently the challenge of delivering Bi to 
the target must be met whether it by selection of appropriate ligands for the development of Bi complexes 
or design of bespoke organobismuth compounds. 
Radiometals such as 212Bi and 213Bi are also used to develop therapeutic radiopharmaceuticals. 
Radiotherapy is the use of high energy radiation to kill cancer cells and shrink tumours. 212Bi and 213Bi 
are α-emitting radionuclides with half-lives of 60.6 and 45.6 min respectively [126]. α-Emitting 212Bi 
and 213Bi containing radiopharmaceuticals should be ideally suited to treat cancer as the short particle 
range and high energy deposition can be used to kill cancer cells by damaging DNA directly after 
administration of a dose at a tumour site [127]. Such radiation could be used to target tumours defective 
in double strand breaks repair mechanisms for example. In addition they decay ultimately to stable 
isotopes and offer less radiotoxicity, as compared to β−-emitters for example, due to their shorter particle 
range. 213Bi is thought to be best suited though, as one of the daughter radionuclides associated with 
212Bi is 208Tl, which emits a 2.6 MeV gamma ray. 
A number of targeted 212Bi and 213Bi-based therapeutic radiopharmaceuticals have been developed 
and even assessed in preclinical and clinical trials involving cancer patients with leukemia, melanoma, 
and glioblastoma [127–132]. Ideally radiopharmaceuticals should have high tumour uptake, a high tumour 
to background ratio, long residence time and fast renal clearance [127]. Targeted radiopharmaceuticals 
generally consist of a bifunctional chelate (BFC), which simultaneously binds a radiometal and often via 
a linker, a targeting biomolecule such as a peptide or monoclonal antibody [3]. 
Typical chelating agents, which are functionalised, include for instance diethylenetriamine 
pentaacetic acid, DTPA, Figure 21a, and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, DOTA, 
Figure 21b. Song et al. developed for example a novel bifunctional chelate ligand, 3p-C-DEPA, for use 
in targeted α-radioimmunotherapy (RIT) of 212Bi and 213Bi. The bifunctional ligand was conjugated with 
trastuzumab, Figure 21c, a human epidermal growth factor receptor 2 (HER2) targeting antibody, which 
selectively targets the HER2 protein overexpressed in particular cancers including 90% of colorectal 
cancers [126]. 
Cherel and co-workers recently investigated the potential of 213Bi radioimmunotherapy in a murine 
model of multiple myeloma [131]. Specifically they wished to establish efficacy in multiple myeloma 
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minimal residual disease treatment in mice with low tumour burden. An antimouse CD138 antibody was 
radiolabelled with 213Bi where the antibody was modified with the 2-(4-isothiocyanatobenzyl)-cyclohexyl-
DTPA chelator. CD138 antigen was targeted as it is strongly expressed on myeloma cells in all patients. 
RIT at 3.7 and 7.4 MBq exhibited a median survival greater than 303 and 227 days respectively as 
compared to the untreated control groups 45.5 days. Furthermore only moderate and transient toxicity 
was associated with treatment [131]. 
Figure 21. Structures of (a) DTPA and (b) DOTA, which are representative examples of 
common chelating agents for 212Bi and 213B. (c) Representation of 3p-C-DEPA conjugated 
to trastuzumab. 
 
Wild et al. reported on the efficacy of two α-emitting 213Bi-labelled peptides, 213Bi-DOTA-PESIN 
and 213Bi-AMBA in a human prostate cancer xenograft model, where PESIN is PEG4-bombesin and 
AMBA is DO3A-CH2CO-8-aminooctanoyl-Q-W-A-V-G-H-L-M-NH2) for peptide-receptor radio-nuclide 
therapy (PRRT). It is noteworthy that potential advantages of PRRT using small peptides over RIT is 
lack of immunogenicity, fast diffusion and fast blood clearance, which can complement 213Bi half-life 
of 45.6 min [129]. The peptides are analogues of gastrin releasing peptide (GRP) and target the GRP 
receptor, which is expressed on all invasive prostatic carcinomas but not benign prostatic tissue at high 
density. Significantly at MTD’s (25 MBq) both 213Bi-labelled peptides were more effective than the 
177Lu-DOTA-PESIN where 177Lu is a β−-emitting isotope, indicating that the α-therapy was found to be 
better than β−-therapy in this study. 
RIT and PRRT with 213Bi-labelled antibodies or peptides respectively have the potential to be safe 
and effective therapeutic approaches. We await the results of ongoing clinical trials with interest. 
Bi may also have a number of indirect roles to play in relation to treating cancer/tackling the incidence 
of cancer. Bi has been linked with the alleviation of side effects associated with cisplatin treatment for 
example [133–135]. Nephrotoxicity is a significant dose-limiting factor in cisplatin-based chemotherapy. 
Administration of Bi(III) salts prior to cisplatin treatment has been shown to depress the renal toxicity 
associated with cisplatin treatment. This renoprotective effect is thought to be due to Bi increasing 
metallothionein production in the kidneys [24,133–135]. More recently, Leussink et al. investigated the 
genomic basis of the renoprotective effect by treating NRK-52E cells, a cell line of rat proximal tubular 
epithelial origin, with Bi(III) salts. Subtraction PCR and microarray techniques were used to detect 
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differentially expressed genes in treated and untreated NRK-52E cells. Down regulated (0.17–0.31-times) 
genes include cytochrome c oxidase subunit I, BAR (an apoptosis regulator), heat-shock protein 70-like 
protein, and ribosomal proteins S7 and L17, and S1, proteins belonging to the translation machinery. 
The single gene to be identified as being upregulated was glutathione S-transferase subunit 3A [136]. 
In addition and as referenced in Section 2, the link between H. pylori and gastric cancer, the second 
most common cause of cancer death in the world, is well established [48,137]. H. pylori-induced chronic 
gastritis can be the first step in the so-called multistep cascade of gastric cancer [138]. In addition and 
more recently H. pylori has been linked with extragastric diseases including gallbladder cancer [49]. 
Therefore the development of effective Bi-based treatments for H. pylori could in turn indirectly have 
positive effects on the incidence of both gastric and gall bladder cancer worldwide. 
6. Conclusions 
Bismuth-based drugs are routinely used for the treatment of gastrointestinal disorders and are found 
as key components of quadruple therapeutic regimens which are becoming increasingly common as  
first-line treatment options for H. pylori. Bismuth also has significant anti-microbial, anti-leishmanial 
and anti-cancer properties. In turn much research has been undertaken recently in relation to the 
synthesis, characterisation and evaluation of novel Bi-based compounds as potential anti-microbial,  
anti-leishmanial and anti-cancer agents. Significantly many of these compounds exhibit excellent 
activity. It is likely that proteins are key biomolecular targets of Bi, particularly proteins which possess 
cysteine (thiol) rich domains or metal binding sites with attractive coordination environments for Bi. 
Metallomic/metalloproteomic approaches will certainly help further elucidate the: (i) mechanism of 
action of Bi on biomolecules; (ii) mechanisms of resistance employed by microbial, protozoan and 
cancer cells and (iii) mechanisms of biological uptake, storage and removal of Bi [139]. 
212Bi and 213Bi containing radiopharmaceuticals also hold much promise as effective α-emitting  
anti-cancer agents. Radiolabelling suitable bifunctional chelating ligands with 212Bi and 213Bi and 
selection of effective targeting biomolecules is the strategy of choice. 
Given the notable resurgence of interest in the bioinorganic chemistry of Bi and development of novel 
classes of Bi compounds with considerable and varied biological activity, it is becoming increasingly 
apparent that Bi does have the potential to play new and important roles in medicinal chemistry. 
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